中华皮肤科杂志 ›› 2019, Vol. 52 ›› Issue (10): 667-710.doi: 10.35541/cjd.20190847
• 指南与共识 • 下一篇
中华医学会皮肤性病学分会银屑病专业委员会
收稿日期:
2019-08-22
修回日期:
2019-09-12
发布日期:
2019-09-30
通讯作者:
张学军
E-mail:ayzxj@vip.sina.com
Committee on Psoriasis, Chinese Society of Dermatology
Received:
2019-08-22
Revised:
2019-09-12
Published:
2019-09-30
Contact:
Xuejun Zhang
E-mail:ayzxj@vip.sina.com
摘要: 【摘要】 银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病,典型临床表现为鳞屑性红斑或斑块,局限或广泛分布,无传染性,治疗困难,常罹患终身。银屑病的病因涉及遗传、免疫、环境等多种因素,通过以T淋巴细胞介导为主、多种免疫细胞共同参与的免疫反应引起角质形成细胞过度增殖或关节滑膜细胞与软骨细胞发生炎症。中医认为多属血分热毒炽盛,营血亏耗,瘀血阻滞,化燥生风,肌肤失养。银屑病是不可治愈性疾病,目前可使用的治疗药物及方法甚多,选择适合患者的治疗药物和方法,对控制病情,维持长期疗效十分重要。指南的目的就是为了逐渐规范治疗方法,提高治疗效能,尽可能减少不良反应的发生。银屑病的治疗方案应根据患者症状确定,轻度以外用治疗为主,中重度可使用系统治疗,对传统系统性药物治疗效果欠佳的患者可适当选择靶向生物制剂治疗。银屑病的治疗目的以控制症状、改善患者生活质量为主。银屑病药物及治疗方法不断发展,新的成果不断涌现,更新指南的目的是及时将国际国内研究的新的成果及时介绍给国内医师,与全球进展保持同步发展。本指南在前两版中国银屑病诊疗指南的基础上进行补充和修订,以进一步规范中国银屑病诊断与治疗,提高诊疗效率,改善患者生活质量。
中华医学会皮肤性病学分会银屑病专业委员会. [开放获取] 中国银屑病诊疗指南(2018完整版)[J]. 中华皮肤科杂志, 2019,52(10):667-710. doi:10.35541/cjd.20190847
Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition)[J]. Chinese Journal of Dermatology, 2019, 52(10): 667-710.doi:10.35541/cjd.20190847
[1] | 全国银屑病流行调查组. 全国1984年银屑病流行调查报告[J]. 中华皮肤科杂志, 1986,19(5):253⁃261. |
[2] 丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010,24(7):598⁃601. | |
[3] 王晓晖. 西南4省市银屑病流行病学调查研究[J]. 哈尔滨医药, 2017,37(5):426⁃427. | |
[4] Helmick CG, Lee⁃Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 national health and nutrition examination surveys[J]. Am J Prev Med, 2014,47(1):37⁃45. doi: 10.1016/j.amepre.2014.02.012. | |
[5] 赵娜, 吴卫志, 杨平. 银屑病流行病学研究进展[J]. 山东医药, 2013,53(39):95⁃97. doi: 10.3969/j.issn.1002⁃266X.2013.39. 039. | |
[6] 庞春坤, 高婷婷. 中国人群银屑病发病危险因素的Meta分析[J]. 中国麻风皮肤病杂志, 2013,29(4):235⁃238. doi: 10.3969/j.issn.1009⁃1157.2013.04.005. | |
[7] 刘俊伶, 冯燕艳, 普雄明. 银屑病与代谢综合征的流行病学[J]. 实用皮肤病学杂志, 2014,(6):444⁃446,449. doi: 10.11786/ sypfbxzz.1674⁃1293.20140615. | |
[8] 蔡云飞, 吴严, 高兴华. 中国银屑病患者合并代谢综合征患病率的 Meta 分析[J]. 临床和实验医学杂志, 2016,15(7):639⁃642. doi: 10.3969/j.issn.1671⁃4695.2016.07.007. | |
[9] Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis[J]. J Eur Acad Dermatol Venereol, 2011,25(12):1409⁃1414. doi: 10.1111/ j.1468⁃3083.2011.03985.x. | |
[10] | Mease PJ, Helliwell PS. Atlas of psoriatic arthritis[M]. London: Springer, 2008. |
[11] | Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977⁃2000: the EDEN survey[J]. J Invest Dermatol, 2003,120(5):738⁃741. doi: 10.1046/j.1523⁃1747. 2003.12145.x. |
[12] | 张学军, 郑捷. 皮肤性病学[M]. 9版. 北京: 人民卫生出版社, 2018:133. |
[13] | Ayala⁃Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases[J]. Psoriasis (Auckl), 2016,6:7⁃32. doi: 10.2147/PTT.S64950. |
[14] | Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J]. J Invest Dermatol, 2013,133(2):377⁃385. doi: 10.1038/jid.2012.339. |
[15] | Ran D, Cai M, Zhang X. Genetics of psoriasis: a basis for precision medicine[J]. Precision Clinical Medicine, 2019,2(2):120⁃130.doi: 10.1093/pcmedi/pbz011. |
[16] | Winchell SA, Watts RA. Relaxation therapies in the treatment of psoriasis and possible pathophysiologic mechanisms[J]. J Am Acad Dermatol, 1988,18(1 Pt 1):101⁃104. doi: 10.1016/s0190⁃9622(88)70015⁃8. |
[17] | 杨雪琴, 张高明, 张力军. 生物反馈治疗银屑病的探讨[J]. 中华皮肤科杂志, 1993,26(2):119⁃120. |
[18] | Mohla G, Brodell RT. Koebner phenomenon in psoriasis. A common response to skin trauma[J]. Postgrad Med, 1999,106(3):39⁃40. doi: 10.3810/pgm.1999.09.693. |
[19] | Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment[J]. J Dermatol, 2018,45(3):264⁃272. doi: 10.1111/1346⁃8138.14139. |
[20] | Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL⁃17A and limited involvement of IL⁃23 in patients with palmo⁃plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial[J]. J Eur Acad Dermatol Venereol, 2014,28(10):1298⁃1305. doi: 10.1111/jdv.12272. |
[21] | Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin⁃17A in patients with psoriatic arthritis[J]. N Engl J Med, 2015,373(14):1329⁃1339. doi: 10.1056/NEJMoa 1412679. |
[22] | Lallas A, Kyrgidis A, Tzellos TG, et al. Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea[J]. Br J Dermatol, 2012,166(6):1198⁃1205. doi: 10.1111/j.1365⁃2133.2012.10868.x. |
[23] | 徐晨琛, 刘洁, 陈典, 等. 皮肤镜在寻常型银屑病与慢性湿疹鉴别诊断中的意义[J]. 中华医学杂志, 2014,(36):2833⁃2837. doi: 10.3760/cma.j.issn.0376⁃2491.2014.36.008. |
[24] | Kim GW, Jung HJ, Ko HC, et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrhoeic dermatitis[J]. Br J Dermatol, 2011,164(3):652⁃656. doi: 10.1111/j.1365⁃2133.2010.10180.x. |
[25] | Errichetti E, Lacarrubba F, Micali G, et al. Differentiation of pityriasis lichenoides chronica from guttate psoriasis by dermoscopy[J]. Clin Exp Dermatol, 2015,40(7):804⁃806. doi: 10.1111/ced.12580. |
[26] | Abdel⁃Azim NE, Ismail SA, Fathy E. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy[J]. Arch Dermatol Res, 2017,309(4):311⁃314. doi: 10.1007/s00403⁃017⁃1727⁃2. |
[27] | González S, Rajadhyaksha M, Rubinstein G, et al. Characteri⁃zation of psoriasis in vivo by reflectance confocal microscopy[J]. J Med, 1999,30(5⁃6):337⁃356. |
[28] | Ardigo M, Cota C, Berardesca E, et al. Concordance between in vivo reflectance confocal microscopy and histology in the evaluation of plaque psoriasis[J]. J Eur Acad Dermatol Venereol, 2009,23(6):660⁃667. doi: 10.1111/j.1468⁃3083.2009. 03134.x. |
[29] | Zhong LS, Wei ZP, Liu YQ. Sensitivity and specificity of Munro microabscess detected by reflectance confocal microscopy in the diagnosis of psoriasis vulgaris[J]. J Dermatol, 2012,39(3):282⁃283. doi: 10.1111/j.1346⁃8138.2011.01366.x. |
[30] | 钟连生, 金鑫, 权晟, 等. 皮肤三维CT在寻常性银屑病诊断中的应用[J]. 中国皮肤性病学杂志, 2011,25(8):607⁃608. |
[31] | Gupta AK, Turnbull DH, Harasiewicz KA, et al. The use of high⁃frequency ultrasound as a method of assessing the severity of a plaque of psoriasis[J]. Arch Dermatol, 1996,132(6):658⁃662. |
[32] | El⁃Zawahry MB, Abdel El⁃Hameed El⁃Cheweikh HM, Abd⁃El⁃Rahman Ramadan S, et al. Ultrasound biomicroscopy in the diagnosis of skin diseases[J]. Eur J Dermatol, 2007,17(6):469⁃475. doi: 10.1684/ejd.2007.0261. |
[33] | Reed WB, Becker SW, Rohde R, et al. Psoriasis and arthritis. Clinicopathologic study[J]. Arch Dermatol, 1961,83:541⁃548. doi: 10.1001/archderm.1961.01580100005001. |
[34] | Henseler T, Christophers E. Disease concomitance in psoriasis[J]. J Am Acad Dermatol, 1995,32(6):982⁃986. doi: 10.1016/0190⁃9622(95)91336⁃x. |
[35] | Gerdes S, Mrowietz U. Comorbidities and psoriasis. Impact on clinical practice[J]. Hautarzt, 2012,63(3):202⁃213. doi: 10.1007/ s00105⁃011⁃2230⁃x. |
[36] | Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology[J]. J Am Acad Dermatol, 2017,76(3):377⁃390. doi: 10.1016/j.jaad.2016.07.064. |
[37] | Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co⁃morbid conditions[J]. J Invest Dermatol, 2010,130(7):1785⁃1796. doi: 10.1038/jid.2010.103. |
[38] | Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: implications for management[J]. J Am Acad Dermatol, 2017,76(3):393⁃403. doi: 10.1016/j.jaad.2016.07.065. |
[39] | Radtke MA, Mrowietz U, Feuerhahn J, et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis[J]. J Dtsch Dermatol Ges, 2015,13(7):674⁃690. doi: 10.1111/ddg.12643. |
[40] | Daudén E, Castañeda S, Suárez C, et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis[J]. J Eur Acad Dermatol Venereol, 2013,27(11):1387⁃1404. doi: 10.1111/jdv.12024. |
[41] | Carvalho AV, Romiti R, Souza CD, et al. Psoriasis comorbidities: complications and benefits of immunobiological treatment[J]. An Bras Dermatol, 2016,91(6):781⁃789. doi: 10.1590/abd1806⁃4841.20165080. |
[42] | Queiro R, Lorenzo A, Tejón P, et al. Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease[J]. Clin Rheumatol, 2019,38(8):2063⁃2068. doi: 10.1007/s10067⁃019⁃04519⁃z. |
[43] | Krasnova TN, Samokhodskaya LM, Ivanitsky LV, et al. Impact of interleukin⁃10 and interleukin⁃28 gene polymorphisms on the development and course of lupus nephritis[J]. Ter Arkh, 2015,87(6):40⁃44. doi: 10.17116/terarkh201587640⁃44. |
[44] | Shen J, Wong KT, Cheng IT, et al. Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease[J]. Ann Rheum Dis, 2017,76(7):1237⁃1244. doi: 10.1136/annrheumdis⁃2016⁃210390. |
[45] | Picard D, Bénichou J, Sin C, et al. Increased prevalence of psoriasis in patients with coronary artery disease: results from a case⁃control study[J]. Br J Dermatol, 2014,171(3):580⁃587. doi: 10.1111/bjd.13155. |
[46] | Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis[J]. JAMA, 2006,296(14):1735⁃1741. doi: 10.1001/jama.296.14.1735. |
[47] | Wu JJ, Guérin A, Sundaram M, et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor⁃α inhibitors versus methotrexate[J]. J Am Acad Dermatol, 2017,76(1):81⁃90. doi: 10.1016/j.jaad.2016.07.042 |
[48] | Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti⁃tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register[J]. Arthritis Rheum, 2007,56(9):2905⁃2912. doi: 10.1002/art.22809. |
[49] | Neimann AL, Shin DB, Wang X, et al. Prevalence of cardio⁃vascular risk factors in patients with psoriasis[J]. J Am Acad Dermatol, 2006,55(5):829⁃835. doi: 10.1016/j.jaad.2006.08.040. |
[50] | Jensen P, Skov L. Psoriasis and obesity[J]. Dermatology, 2016,232(6):633⁃639. doi: 10.1159/000455840. |
[51] | Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross⁃sectional study[J]. Dermatology, 2008,216(2):152⁃155. doi: 10.1159/000111 512. |
[52] | Upala S, Sanguankeo A. Effect of lifestyle weight loss inter⁃vention on disease severity in patients with psoriasis: a systematic review and meta⁃analysis[J]. Int J Obes (Lond), 2015,39(8):1197⁃1202. doi: 10.1038/ijo.2015.64. |
[53] | Cao H. Adipocytokines in obesity and metabolic disease[J]. J Endocrinol, 2014,220(2):T47⁃T59. doi: 10.1530/JOE⁃13⁃0339. |
[54] | Kruglikov IL, Wollina U. Local effects of adipose tissue in psoriasis and psoriatic arthritis[J]. Psoriasis (Auckl), 2017,7:17⁃25. doi: 10.2147/PTT.S122959. |
[55] | Murray ML, Bergstresser PR, Adams⁃Huet B, et al. Relation⁃ship of psoriasis severity to obesity using same⁃gender siblings as controls for obesity[J]. Clin Exp Dermatol, 2009,34(2):140⁃144. doi: 10.1111/j.1365⁃2230.2008.02791.x. |
[56] | Gui XY, Yu XL, Jin HZ, et al. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital⁃based cross⁃sectional study[J]. J Diabetes Investig, 2018,9(1):39⁃43. doi: 10.1111/jdi.12663. |
[57] | Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines[J]. Circulation, 2004,110(2):227⁃239. doi: 10.1161/01.CIR.0000133317.49796.0E. |
[58] | Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV⁃A radiation (PUVA). A meta⁃analysis[J]. Arch Dermatol, 1998,134(12):1582⁃1585. doi: 10. 1001/archderm.134.12.1582. |
[59] | Christophers E. Periodontitis and risk of psoriasis: another comorbidity[J]. J Eur Acad Dermatol Venereol, 2017,31(5):757⁃758. doi: 10.1111/jdv.14249. |
[60] | Papadavid E, Dalamaga M, Vlami K, et al. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital⁃based case⁃control study[J]. Sleep Breath, 2017,21(4):949⁃958. doi: 10.1007/s11325⁃017⁃1507⁃4. |
[61] | Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: a population⁃based study in Taiwan[J]. J Eur Acad Dermatol Venereol, 2012,26(1):59⁃65. doi: 10.1111/j.1468⁃3083.2011.04009.x. |
[62] | Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis[J]. Arthritis Res Ther, 2011,13(1):R16. doi: 10.1186/ar3240. |
[63] | Molina⁃Leyva A, Jiménez⁃Moleón JJ, Naranjo⁃Sintes R, et al. Sexual dysfunction in psoriasis: a systematic review[J]. J Eur Acad Dermatol Venereol, 2015,29(4):649⁃655. doi: 10.1111/jdv.12845. |
[64] | Parsi KK, Brezinski EA, Lin TC, et al. Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists[J]. J Am Acad Dermatol, 2012,67(3):357⁃362. doi: 10.1016/j.jaad.2011.09.006. |
[65] | Alamdari HS, Gustafson CJ, Davis SA, et al. Psoriasis and cardiovascular screening rates in the United States[J]. J Drugs Dermatol, 2013,12(1):e14⁃e19. |
[66] | 中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志, 2014,47(3):213⁃215. doi: 10.3760/cma.j.issn.0412⁃4030.2014.03.017. |
[67] | Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis[J]. Am J Clin Dermatol, 2014,15(6):467⁃478. doi: 10.1007/s40257⁃014⁃0097⁃1. |
[68] | Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents[J]. J Am Acad Dermatol, 2009,61(3):451⁃485. doi: 10.1016/j.jaad.2009.03.027. |
[69] | Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: a work in progress[J]. Cutis, 2018,101(3S):10⁃12. |
[70] | Gelmetti C. Therapeutic moisturizersas adjuvant therapy for psoriasis patients[J]. Am J Clin Dermatol, 2009,10(Suppl 1):7⁃12. doi: 10.2165/0128071⁃200910001⁃00002. |
[71] | Harcharik S, Emer J. Steroid⁃sparing properties of emollients in dermatology[J]. Skin Therapy Lett, 2014,19(1):5⁃10. |
[72] | Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy[J]. J Dermatolog Treat, 2003,14(1):8⁃13. |
[73] | 任发亮, 常宝珠, 陈旭, 等. 0.005%卡泊三醇软膏治疗寻常型银屑病文献回顾[J]. 中国中西医结合皮肤性病学杂志, 2012,11(6):341⁃344. doi: 10.3969/j.issn.1672⁃0709.2012.06. 001. |
[74] | Koo JY, Lowe NJ, Lew⁃Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis[J]. J Am Acad Dermatol, 2000,43(5 Pt 1):821⁃828. doi: 10.1067/mjd.2000.107 940. |
[75] | Carrascosa JM, Vanaclocha F, Borrego L, et al. Update of the topical treatment of psoriasis[J]. Actas Dermosifiliogr, 2009,100(3):190⁃200. |
[76] | Daniel BS, Orchard D. Ocular side⁃effects of topical corticos⁃teroids: what a dermatologist needs to know[J]. Australas J Dermatol, 2015,56(3):164⁃169. doi: 10.1111/ajd.12292. |
[77] | 于霖, 李虹, 刘克英. Goeckerman疗法配合中药治疗银屑病临床疗效观察[J]. 中国皮肤性病学杂志, 2004,18(1):31⁃31. doi: 10.3969/j.issn.1001⁃7089.2004.01.016. |
[78] | Ortiz Z, Shea B, Suarez⁃Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials[J]. J Rheumatol, 1998,25(1):36⁃43. |
[79] | Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis[J]. J Am Acad Dermatol, 1993,28(3):466⁃469. doi: 10.1016/0190⁃9622(93)70069⁃6. |
[80] | Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis[J]. Expert Rev Clin Immunol, 2015,11(5):553⁃563. doi: 10.1586/1744666X.2015.1026894. |
[81] | Fridlington JL, Tripple JW, Reichenberg JS, et al. Acute methotrexate toxicity seen as plaque psoriasis ulceration and necrosis: a diagnostic clue[J]. Dermatol Online J, 2011,17(11):2. |
[82] | Moreira DM, da Silva RL, Vieira JL, et al. Role of vascular inflammation in coronary artery disease: potential of anti⁃inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti⁃inflammatory drugs in coronary artery disease[J]. Am J Cardiovasc Drugs, 2015,15(1):1⁃11. doi: 10.1007/s40256⁃014⁃0094⁃z. |
[83] | Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti⁃inflammatory drugs in patients with severe psoriasis: 5⁃year follow⁃up of a Danish nationwide cohort[J]. J Eur Acad Dermatol Venereol, 2015,29(6):1128⁃1134. doi: 10. 1111/jdv.12768. |
[84] | Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review[J]. Rheumatology (Oxford), 2010,49(2):295⁃307. doi: 10.1093/rheumatology/kep366. |
[85] | Kivity S, Zafrir Y, Loebstein R, et al. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients[J]. Autoimmun Rev, 2014,13(11):1109⁃1113. doi: 10.1016/j.autrev.2014.08.027. |
[86] | Morison WL, Momtaz K, Parrish JA, et al. Combined methotrexate⁃PUVA therapy in the treatment of psoriasis[J]. J Am Acad Dermatol, 1982,6(1):46⁃51. doi: 10.1016/s0190⁃9622 (82)70005⁃2. |
[87] | Raaby L, Zachariae C, Østensen M, et al. Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a Danish expert meeting[J]. Acta Derm Venereol, 2017,97(4):426⁃432. doi: 10.2340/00015555⁃2599. |
[88] | Carretero G, Puig L, Dehesa L, et al. Guidelines on the use of methotrexate in psoriasis[J]. Actas Dermosifiliogr, 2010,101(7):600⁃613. doi: 10.1016/j.ad.2010.04.002. |
[89] | Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population⁃based cohort study in the United Kingdom[J]. Arch Dermatol, 2003,139(11):1425⁃1429. doi: 10.1001/archderm.139. 11.1425. |
[90] | Weber⁃Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low⁃dose methotrexate: an observational cohort study[J]. Rheumatology (Oxford), 2014,53(4):757⁃763. doi: 10.1093/rheumatology/ket390. |
[91] | Gromnica⁃Ihle E, Krüger K. Use of methotrexate in young patients with respect to the reproductive system[J]. Clin Exp Rheumatol, 2010,28(5 Suppl 61):S80⁃S84. |
[92] | Nast A, Jacobs A, Rosumeck S, et al. Methods report: European S3⁃guidelines on the systemic treatment of psoriasis vulgaris⁃⁃update 2015⁃⁃EDF in cooperation with EADV and IPC[J]. J Eur Acad Dermatol Venereol, 2015,29(12):e1⁃e22. doi: 10.1111/ jdv.13353. |
[93] | Dadlani C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature[J]. J Am Acad Dermatol, 2005,52(2):316⁃340. doi: 10.1016/j.jaad.2004.07.043. |
[94] | Mueller W, Herrmann B. Cyclosporin A for psoriasis[J]. N Engl J Med, 1979,301(10):555. doi: 10.1056/NEJM19790906 3011016. |
[95] | Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I[J]. J Am Acad Dermatol, 2010,63(6):925⁃ 948. doi: 10.1016/j.jaad.2010.02.063. |
[96] | Berth⁃Jones J. The use of ciclosporin in psoriasis[J]. J Dermatolog Treat. 2005,16(5⁃6):258⁃277. |
[97] | Griffiths CE, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement[J]. Br J Dermatol, 2004,150 Suppl 67:11⁃23. doi: 10.1111/j.0366⁃077X.2004.05949.x. |
[98] | Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis[J]. J Am Acad Dermatol, 1998,39(3):464⁃475. doi: 10.1016/s0190⁃9622(98)70325⁃1. |
[99] | Pathirana D, Ormerod AD, Saiag P, et al. European S3⁃guidelines on the systemic treatment of psoriasis vulgaris[J]. J Eur Acad Dermatol Venereol, 2009,23 Suppl 2:1⁃70. doi: 10. 1111/j.1468⁃3083.2009.03389.x. |
[100] | Camp RD, Reitamo S, Friedmann PS, et al. Cyclosporin A in severe, therapy⁃resistant atopic dermatitis: report of an international workshop, April 1993[J]. Br J Dermatol, 1993,129(2):217⁃220. |
[101] | Griffiths CE, Katsambas A, Dijkmans BA, et al. Update on the use of ciclosporin in immune⁃mediated dermatoses[J]. Br J Dermatol, 2006,155 Suppl 2:1⁃16. doi: 10.1111/j.1365⁃2133. 2006.07343.x. |
[102] | Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis[J]. Health Technol Assess, 2000,4(40):1⁃125. |
[103] | Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis. Results of a meta⁃analysis in 579 patients[J]. Am J Clin Dermatol, 2001,2(1):41⁃47. doi: 10.2165/00128071⁃200102010⁃00007. |
[104] | Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1⁃year multicentre, randomized study. The PISCES Study Group[J]. Br J Dermatol, 1999,141(2):283⁃291. doi: 10.1046/j.1365⁃2133.1999.02977.x. |
[105] | Berth⁃Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study[J]. Br J Dermatol, 1997,136(4):527⁃530. |
[106] | Colombo D, Cassano N, Altomare G, et al. Psoriasis relapse evaluation with week⁃end cyclosporine A treatment: results of a randomized, double⁃blind, multicenter study[J]. Int J Immunopathol Pharmacol, 2010,23(4):1143⁃1152. doi: 10.1177/ 039463201002300418. |
[107] | Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy[J]. J Am Acad Dermatol, 2010,62(1):114⁃135. doi: 10.1016/j.jaad.2009.08.026. |
[108] | Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference[J]. J Am Acad Dermatol, 2010,62(5):838⁃853. doi: 10.1016/j.jaad.2009.05.017. |
[109] | Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy[J]. J Am Acad Dermatol, 1993,28(3):454⁃459. doi: 10.1016/0190⁃9622(93)70067⁃4. |
[110] | Ho VC, Griffiths CE, Berth⁃Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long⁃term management of psoriasis: a 2⁃year cohort study[J]. J Am Acad Dermatol, 2001,44(4):643⁃651. doi: 10.1067/mjd.2001.112400. |
[111] | Levell NJ, Shuster S, Munro CS, et al. Remission of ordinary psoriasis following a short clearance course of cyclosporin[J]. Acta Derm Venereol, 1995,75(1):65⁃69. doi: 10.2340/0001 5555756569. |
[112] | Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis[J]. Clin Exp Dermatol, 2001,26(6):480⁃483. doi: 10.1046/j.1365⁃2230.2001.00870.x. |
[113] | Balasubramaniam P, Stevenson O, Berth⁃Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities[J]. Br J Dermatol, 2004,150(4):741⁃746. doi: 10.1111/j.0007⁃0963.2004.05739.x. |
[114] | Roenigk HH Jr. Acitretin combination therapy[J]. J Am Acad Dermatol, 1999,41(3 Pt 2):S18⁃S21. doi: 10.1016/s0190⁃9622(99)70361⁃0. |
[115] | Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis[J]. Br J Dermatol, 1999,141(2):279⁃282. doi: 10.1046/ j.1365⁃2133.1999.02976.x. |
[116] | Kuijpers AL, van Dooren⁃Greebe JV, van de Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis[J]. Dermatology, 1997,194(1):88⁃90. doi: 10.1159/000246070. |
[117] | Griffiths CE, Powles AV, McFadden J, et al. Long⁃term cyclosporin for psoriasis[J]. Br J Dermatol, 1989,120(2):253⁃260. doi: 10.1111/j.1365⁃2133.1989.tb07790.x. |
[118] | Gottlieb SL, Heftler NS, Gilleaudeau P, et al. Short⁃contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study[J]. J Am Acad Dermatol, 1995,33(4):637⁃645. doi: 10.1016/0190⁃9622(95)91286⁃x. |
[119] | Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low⁃dose cyclosporine: results of a multicenter placebo⁃controlled study[J]. J Am Acad Dermatol, 1994,31(1):68⁃74. doi: 10.1016/s0190⁃9622(94)70138⁃5. |
[120] | Sarzi⁃Puttini P, Cazzola M, Panni B, et al. Long⁃term safety and efficacy of low⁃dose cyclosporin A in severe psoriatic arthritis[J]. Rheumatol Int, 2002,21(6):234⁃238. |
[121] | Somech R, Doyle J. Pseudotumor cerebri after allogeneic bone marrow transplant associated with cyclosporine a use for graft⁃versus⁃host disease prophylaxis[J]. J Pediatr Hematol Oncol, 2007,29(1):66⁃68. doi: 10.1097/MPH.0b013e318030ac3b. |
[122] | Higgins E, Munro C, Marks J, et al. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A[J]. Br J Dermatol, 1989,121(1):71⁃74. doi: 10.1111/j.1365⁃2133.1989.tb01402.x. |
[123] | Orfanos CE, Zouboulis CC, Almond⁃Roesler B, et al. Current use and future potential role of retinoids in dermatology[J]. Drugs, 1997,53(3):358⁃388. doi: 10.2165/00003495⁃1997530 30⁃00003. |
[124] | Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine[J]. Clin Dermatol, 2008,26(5):438⁃447. doi: 10.1016/j.clindermatol.2007.11.006. |
[125] | McNamara PJ, Jewell RC, Jensen BK, et al. Food increases the bioavailability of acitretin[J]. J Clin Pharmacol, 1988,28(11):1051⁃1055. doi: 10.1002/j.1552⁃4604.1988.tb03129.x. |
[126] | Brindley CJ. Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10⁃1670, etretin)[J]. Dermatologica, 1989,178(2):79⁃87. doi: 10.1159/000248397. |
[127] | Berbis P. Retinoids: mechanisms of action[J]. Ann Dermatol Venereol, 2010,137 Suppl 3:S97⁃S103. doi: 10.1016/S0151⁃9638(10)70036⁃3. |
[128] | Webber IR, Back DJ. Effect of etretinate on cyclosporin metabolism in vitro[J]. Br J Dermatol, 1993,128(1):42⁃44. doi: 10.1111/j.1365⁃2133.1993.tb00145.x. |
[129] | Daudén E, Puig L, Ferrándiz C, et al. Consensus document on the evaluation and treatment of moderate⁃to⁃severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology[J]. J Eur Acad Dermatol Venereol, 2016,30 Suppl 2:1⁃18. doi: 10.1111/jdv.13542. |
[130] | Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan[J]. J Dermatol, 1999,26(3):141⁃149. doi: 10.1111/j.1346⁃8138.1999.tb03444.x. |
[131] | Paul C, Gallini A, Maza A, et al. Evidence⁃based recommen⁃dations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of derma⁃tologists[J]. J Eur Acad Dermatol Venereol, 2011,25 Suppl 2:2⁃11. doi: 10.1111/j.1468⁃3083.2011.03990.x. |
[132] | Sbidian E, Maza A, Montaudié H, et al. Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review[J]. J Eur Acad Dermatol Venereol, 2011,25 Suppl 2:28⁃33. doi: 10.1111/j.1468⁃3083.2011.03993.x. |
[133] | Orfanos CE. Treatment of psoriasis with retinoids: present status[J]. Cutis, 1999,64(5):347⁃353. |
[134] | Gollnick HP. Oral retinoids⁃⁃efficacy and toxicity in psoriasis[J]. Br J Dermatol, 1996,135 Suppl 49:6⁃17. doi: 10.1111/j. 1365⁃2133.1996.tb15661.x. |
[135] | Ling MR. Acitretin: optimal dosing strategies[J]. J Am Acad Dermatol, 1999,41(3 Pt 2):S13⁃S17. doi: 10.1016/s0190⁃9622(99)70360⁃9. |
[136] | Dogra S, Jain A, Kanwar AJ. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study[J]. J Eur Acad Dermatol Venereol, 2013,27(3):e305⁃e311. doi: 10.1111/j.1468⁃3083. 2012.04644.x. |
[137] | Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in a dose⁃dependent fashion[J]. J Am Acad Dermatol, 1988,18(4 Pt 1):655⁃662. doi: 10.1016/s0190⁃9622(88)70086⁃9. |
[138] | Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis[J]. J Am Acad Dermatol, 2004,50(3):416⁃430. doi: 10.1016/j.jaad.2002.12.002. |
[139] | Menter MA, See JA, Amend WJ, et al. Proceedings of the psoriasis combination and rotation therapy conference. Deer Valley, Utah, Oct. 7⁃9, 1994[J]. J Am Acad Dermatol, 1996,34(2 Pt 1):315⁃321. doi: 10.1016/s0190⁃9622(96)80148⁃4. |
[140] | Munro DD. Azathioprine in psoriasis[J]. Proc R Soc Med, 1973,66(8):747⁃748. |
[141] | Dalaker M, Bonesrønning JH. Long⁃term maintenance treatment of moderate⁃to⁃severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retro⁃spective cohort[J]. J Eur Acad Dermatol Venereol, 2009,23(3):277⁃282. doi: 10.1111/j.1468⁃3083.2008.03039.x. |
[142] | Menkès CJ, Simon F, Delbarre F. Letter: Treatment of psoriasic polyarthritis by azathioprine[J]. Nouv Presse Med, 1975,4(8):585. |
[143] | Du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine[J]. Br Med J, 1974,1(5897):49⁃51. doi: 10.1136/bmj.1.5897.49. |
[144] | 中华医学会风湿病学分会. 银屑病关节炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010,14(9):631⁃633. doi: 10.3760/cma.j.issn.1007⁃7480.2010.09.012. |
[145] | Hacker SM, Ramos⁃Caro FA, Ford MJ, et al. Azathioprine: a forgotten alternative for treatment of severe psoriasis[J]. Int J Dermatol, 1992,31(12):873⁃874. doi: 10.1111/j.1365⁃4362. 1992.tb03548.x. |
[146] | Suess A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus ⁃ two sides of a coin[J]. Int J Dermatol, 2008,47(1):83⁃86. doi: 10.1111/j.1365⁃4632.2007.03333.x. |
[147] | 吴实, 邓列华. 来氟米特在皮肤科的应用[J]. 皮肤性病诊疗学杂志, 2012,19(6):396⁃398. |
[148] | 姜红, 任耘, 罗粤. 新型免疫调节剂——来氟米特[J]. 中国新药与临床杂志, 2004,23(7):451⁃454. |
[149] | Awad SS. Leflunomide is a possible deactivator for vitiligo, a pilot study[J]. J Eur Acad Dermatol Venereol, 2012,26(9):1173. doi: 10.1111/j.1468⁃3083.2011.04311.x. |
[150] | Lonsdale⁃Eccles AA, Haworth AE, McCrae FC, et al. Successful treatment of multicentric reticulohistiocytosis with leflunomide[J]. Br J Dermatol, 2009,161(2):470⁃472. doi: 10.1111/j.1365⁃2133.2009.09227.x. |
[151] | Jin D, Duan K, Zhang L, et al. The effects of leflunomide on CD4+CD25+Foxp3+ T regulatory cells in mice receiving allogeneic bone marrow transplantation[J]. Inflamm Res, 2012,61(1):53⁃60. doi: 10.1007/s00011⁃011⁃0388⁃4. |
[152] | Huang JL, Wu SY, Xie XJ, et al. Inhibiting effects of leflunomide metabolite on overexpression of CD147, MMP⁃2 and MMP⁃9 in PMA differentiated THP⁃1 cells[J]. Eur J Pharmacol, 2011,670(1):304⁃310. doi: 10.1016/j.ejphar.2011. 07.045. |
[153] | Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double⁃blind, randomized, placebo⁃controlled clinical trial[J]. Arthritis Rheum, 2004,50(6):1939⁃1950. doi: 10.1002/art.20253. |
[154] | Navarro R, Daudén E, Gallo E, et al. Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature[J]. Skin Pharmacol Physiol, 2012,25(2):107⁃110. doi: 10.1159/000335264. |
[155] | Alcorn N, Saunders S, Madhok R. Benefit⁃risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing[J]. Drug Saf, 2009,32(12):1123⁃1134. doi: 10.2165/11316650⁃000000000⁃00000. |
[156] | Haufs MG, Beissert S, Grabbe S, et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil[J]. Br J Dermatol, 1998,138(1):179⁃181. doi: 10.1046/j.1365⁃2133.1998.02048.x. |
[157] | Zhou Y, Rosenthal D, Dutz J, et al. Mycophenolate mofetil (CellCept) for psoriasis: a two⁃center, prospective, open⁃label clinical trial[J]. J Cutan Med Surg, 2003,7(3):193⁃197. doi: 10.1177/120347540300700302. |
[158] | Grundmann⁃Kollmann M, Mooser G, Schraeder P, et al. Treatment of chronic plaque⁃stage psoriasis and psoriatic arthritis with mycophenolate mofetil[J]. J Am Acad Dermatol, 2000,42(5 Pt 1):835⁃837. doi: 10.1067/mjd.2000.104890. |
[159] | Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients[J]. Br J Dermatol, 2001,144(3):583⁃586. doi: 10.1046/j.1365⁃2133.2001.04088.x. |
[160] | Pedraz J, Daudén E, Delgado⁃Jiménez Y, et al. Sequential study on the treatment of moderate⁃to⁃severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin[J]. J Eur Acad Dermatol Venereol, 2006,20(6):702⁃706. doi: 10.1111/j.1468⁃3083.2006.01577.x. |
[161] | Ji YZ, Geng L, Ma XH, et al. Severe generalized pustular psoriasis treated with mycophenolate mofetil[J]. J Dermatol, 2011,38(6):603⁃605. doi: 10.1111/j.1346⁃8138.2010.01019.x. |
[162] | Halverstam CP, Lebwohl M. Nonstandard and off⁃label therapies for psoriasis[J]. Clin Dermatol, 2008,26(5):546⁃553. doi: 10.1016/j.clindermatol.2007.10.023. |
[163] | Brenner M, Molin S, Ruebsam K, et al. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment[J]. Br J Dermatol, 2009,161(4):964⁃966. doi: 10.1111/j.1365⁃2133.2009.09348.x. |
[164] | Wilson AG, Clark I, Heard SR, et al. Immunoblotting of streptococcal antigens in guttate psoriasis[J]. Br J Dermatol, 1993,128(2):151⁃158. doi: 10.1111/j.1365⁃2133.1993.tb15144.x. |
[165] | Koufakis T, Gabranis I. First presentation of guttate psoriasis triggered by acute tonsillitis[J]. Pan Afr Med J, 2014,17:273. doi: 10.11604/pamj.2014.17.273.421. |
[166] | Walecka I, Olszewska M, Rakowska A, et al. Improvement of psoriasis after antibiotic therapy with cefuroxime axetil[J]. J Eur Acad Dermatol Venereol, 2009,23(8):957⁃958. doi: 10. 1111/j.1468⁃3083.2009.03145.x. |
[167] | Alzolibani AA, Zedan K. Macrolides in chronic inflammatory skin disorders[J]. Mediators Inflamm, 2012,2012:159354. doi: 10.1155/2012/159354. |
[168] | Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris[J]. J Dermatol, 2000,27(8):508⁃512. doi: 10.1111/j.1346⁃8138.2000.tb02217.x. |
[169] | Huang SW, Chen YJ, Wang ST, et al. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod⁃induced psoriasis⁃like skin inflammation in mice[J]. J Dermatol Sci, 2016,84(1):59⁃70. doi: 10.1016/j.jdermsci. 2016.07.007. |
[170] | Tsankov N, Grozdev I. Rifampicin⁃⁃a mild immunosuppressive agent for psoriasis[J]. J Dermatolog Treat, 2011,22(2):62⁃64. doi: 10.3109/09546630903496975. |
[171] | Tsankov N, Grozdev I, Kkzandjieva J. Old drug⁃⁃new indication. Rifampicin in psoriasis[J]. J Dermatolog Treat, 2006,17(1):18⁃23. doi: 10.1080/09546630500375643. |
[172] | 赵飞, 李红文, 何秋波. 甲砜霉素对小儿泛发性脓疱型银屑病的治疗观察[J]. 中国麻风皮肤病杂志, 2004,20(3):240⁃241. |
[173] | 周凌, 伍津津, 吴先林, 等. 硫酸镁联合甲砜霉素治疗泛发性脓疱型银屑病的临床疗效观察[J]. 中国皮肤性病学杂志, 2003,17(5):318⁃319. |
[174] | Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus[J]. Arch Dermatol Res, 2011,303(1):1⁃10. doi: 10.1007/s00403⁃010⁃1080⁃1. |
[175] | Felson DT, Anderson JJ, Boers M, et al. American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis[J]. Arthritis Rheum, 1995,38(6):727⁃735. doi: 10.1002/art.1780380602. |
[176] | González⁃Álvaro I, Martínez⁃Fernández C, Dorantes⁃Calderón B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis[J]. Rheumatology (Oxford), 2015,54(7):1200⁃1209. doi: 10.1093/rheumatology/keu461. |
[177] | Mrowietz U, Kragballe K, Nast A, et al. Strategies for improving the quality of care in psoriasis with the use of treatment goals⁃⁃a report on an implementation meeting[J]. J Eur Acad Dermatol Venereol, 2011,25 Suppl 3:1⁃13. doi: 10.1111/j.1468⁃3083.2011.04033.x. |
[178] | Paller AS, Siegfried EC, Pariser DM, et al. Long⁃term safety and efficacy of etanercept in children and adolescents with plaque psoriasis[J]. J Am Acad Dermatol, 2016,74(2):280⁃287.e1⁃3. doi: 10.1016/j.jaad.2015.09.056. |
[179] | 黄琼, 杨勤萍, 方栩, 等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲试验[J]. 中华皮肤科杂志, 2007,40(11):655⁃658. |
[180] | 李诚让, 杨雪源, 顾军, 等. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中重度寻常性银屑病的多中心临床研究[J]. 中华皮肤科杂志, 2015,(8):547⁃550. doi: 10.3760/cma.j.issn.0412⁃4030.2015.08.007. |
[181] | Xie F, Wang R, Zhao ZG, et al. Safety and efficacy of etanercept monotherapy for moderate⁃to⁃severe plaque psoriasis: a prospective 12⁃week follow⁃up study[J]. J Huazhong Univ Sci Technolog Med Sci, 2017,37(6):943⁃947. doi: 10.1007/s11596⁃017⁃1832⁃7. |
[182] | Nast A, Gisondi P, Ormerod AD, et al. European S3⁃guidelines on the systemic treatment of psoriasis vulgaris⁃⁃Update 2015⁃⁃short version⁃⁃EDF in cooperation with EADV and IPC[J]. J Eur Acad Dermatol Venereol, 2015,29(12):2277⁃2294. doi: 10. 1111/jdv.13354. |
[183] | Kimball AB, Rothman KJ, Kricorian G, et al. OBSERVE⁃5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5⁃year results[J]. J Am Acad Dermatol, 2015,72(1):115⁃122. doi: 10.1016/j.jaad. 2014.08.050. |
[184] | Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial[J]. Lancet, 2005,366(9494):1367⁃1374. doi: 10.1016/S0140⁃6736(05)67566⁃6. |
[185] | Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate⁃to⁃severe plaque psoriasis[J]. J Am Acad Dermatol, 2007,56(1):31.e1⁃e15. doi: 10.1016/j.jaad.2006.07.017. |
[186] | Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double⁃blind, placebo⁃controlled multicenter trial[J]. Chin Med J (Engl), 2012,125(11):1845⁃1851. |
[187] | Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: results from a phase 3, randomized, placebo⁃controlled, double⁃blind study[J]. J Eur Acad Dermatol Venereol, 2017,31(1):89⁃95. doi: 10.1111/jdv.13746. |
[188] | Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial[J]. J Am Acad Dermatol, 2008,58(1):106⁃115. doi: 10.1016/ j.jaad.2007.09.010. |
[189] | Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL[J]. J Am Acad Dermatol, 2012,66(2):241⁃251. doi: 10.1016/j.jaad.2010. 12.005. |
[190] | Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque⁃type psoriasis: results from a phase 3 clinical trial (LOTUS)[J]. J Drugs Dermatol, 2013,12(2):166⁃174. |
[191] | Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 76⁃week results from a randomised, double⁃blind, placebo⁃controlled trial (PHOENIX 1)[J]. Lancet, 2008,371(9625):1665⁃1674. doi: 10.1016/S0140⁃ 6736(08)60 725⁃4. |
[192] | Papp KA, Griffiths CE, Gordon K, et al. Long⁃term safety of ustekinumab in patients with moderate⁃to⁃severe psoriasis: final results from 5 years of follow⁃up[J]. Br J Dermatol, 2013,168(4):844⁃854. doi: 10.1111/bjd.12214. |
[193] | Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate⁃to⁃severe plaque psoriasis up to 1 year: results from the CLEAR study[J]. J Am Acad Dermatol, 2017,76(1):60⁃69. doi: 10. 1016/j.jaad.2016.08.008. |
[194] | Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial[J]. J Am Acad Dermatol, 2015,73(3):400⁃409. doi: 10.1016/j.jaad.2015.05.013. |
[195] | Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis⁃⁃results of two phase 3 trials[J]. N Engl J Med, 2014,371(4):326⁃338. doi: 10.1056/NEJMoa1314258. |
[196] | Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate⁃to⁃severe psoriasis (UNCOVER⁃2 and UNCOVER⁃3): results from two phase 3 randomised trials[J]. Lancet, 2015,386(9993):541⁃51. doi: 10.1016/S0140⁃6736(15)60125⁃8. |
[197] | Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate⁃to⁃severe psoriasis: 24⁃week results from IXORA⁃S, a phase III study[J]. Br J Dermatol, 2017,177(4):1014⁃1023. doi: 10.1111/bjd.15666. |
[198] | Lesner K, Reich A, Szepietowski JC, et al. Determinants of psychosocial health in psoriatic patients: a multi⁃national study[J]. Acta Derm Venereol, 2017,97(10):1182⁃1188. doi: 10.2340/ 00015555⁃2760. |
[199] | 杨伟琴, 黄林婷, 鲁智勇, 等. 银屑病患者健康教育研究进展[J]. 中国麻风皮肤病杂志, 2016,32(11):695⁃698. |
[200] | 王爱燕, 崔艳霞, 张华梅, 等. 银屑病患者心理行为干预的研究进展[J]. 中国医药指南, 2017,15(1):16⁃17. |
[201] | Wu W, Debbaneh M, Moslehi H, et al. Tonsillectomy as a treatment for psoriasis: a review[J]. J Dermatolog Treat, 2014,25(6):482⁃486. doi: 10.3109/09546634.2013.848258. |
[202] | 张福仁, 田仁明, 马世尧, 等. 雷公藤治疗进行期寻常型银屑病的随机双盲研究[J]. 临床皮肤科杂志, 1999,28(1):32⁃33. |
[203] | Khosravi H, Siegel MP, Van Voorhees AS, et al. Treatment of inverse/intertriginous psoriasis: updated guidelines from the Medical Board of the National Psoriasis Foundation[J]. J Drugs Dermatol, 2017,16(8):760⁃766. |
[204] | Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the Medical Board of the National Psoriasis Foundation[J]. J Am Acad Dermatol, 2010,62(4):655⁃662. doi: 10.1016/j.jaad.2009.05.048. |
[205] | Lewis TG, Tuchinda C, Lim HW, et al. Life⁃threatening pustular and erythrodermic psoriasis responding to infliximab[J]. J Drugs Dermatol, 2006,5(6):546⁃548. |
[206] | Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation[J]. J Am Acad Dermatol, 2012,67(2):279⁃288. doi: 10.1016/j.jaad.2011.01.032. |
[207] | Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan[J]. J Dermatol, 1999,26(3):141⁃149. doi: 10.1111/j.1346⁃8138.1999.tb03444.x. |
[208] | Esposito M, Mazzotta A, Casciello C, et al. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series[J]. Dermatology, 2008,216(4):355⁃360. doi: 10.1159/000117706. |
[209] | Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin⁃1⁃receptor antagonist Anakinra: lack of correlation with IL1RN mutations[J]. Ann Intern Med, 2010,153(1):66⁃67. doi: 10.7326/0003⁃4819⁃153⁃1⁃201007060⁃00030. |
[210] | 郑和义, 王宏伟, 王家璧, 等. 雷公藤治疗脓疱型银屑病7例[J]. 中国皮肤性病学杂志, 1998,12(3):162. |
[211] | Sheu JS, Divito SJ, Enamandram M, et al. Dapsone therapy for pustular psoriasis: case series and review of the literature[J]. Dermatology, 2016,232(1):97⁃101. doi: 10.1159/000431171. |
[212] | Ji YZ, Geng L, Ma XH, et al. Severe generalized pustular psoriasis treated with mycophenolate mofetil[J]. J Dermatol, 2011,38(6):603⁃605. doi: 10.1111/j.1346⁃8138.2010.01019.x. |
[213] | Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options[J]. Int J Dermatol, 2011,50(10):1195⁃1211. doi: 10.1111/j.1365⁃4632.2011.04993.x. |
[214] | Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double⁃blind comparative trial[J]. Br J Dermatol, 1988,119(6):755⁃759. doi: 10.1111/j.1365⁃2133.1988.tb03499.x. |
[215] | 曲大为. 雷公藤多甙治疗掌跖脓疱病23例临床疗效观察[J]. 北京医学, 1997,19(3):150. |
[216] | Reitamo S, Erkko P, Remitz A, et al. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double⁃blind, placebo⁃controlled study. Arch Dermatol, 1993,29(10):1273⁃1279. |
[217] | Thestrup⁃Pedersen K, Reymann F. Treatment of pustulosis palmaris et plantaris with colchicine. A double⁃blind cross⁃over trial[J]. Acta Derm Venereol, 1984,64(1):76⁃78. |
[218] | Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis[J]. J Drugs Dermatol, 2008,7(10):940⁃946. |
[219] | Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update[J]. Ann Rheum Dis, 2016,75(3):499⁃510. doi: 10.1136/ annrheumdis⁃2015⁃208337. |
[220] | Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis[J]. Arthritis Rheumatol, 2016,68(5):1060⁃1071. doi: 10.1002/art.39573. |
[221] | Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis[J]. Ann Rheum Dis, 2005,64(6):859⁃864. doi: 10.1136/ard.2004.024463. |
[222] | Nash P, Thaçi D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in⁃depth analysis of data from the TOPAS study[J]. Dermatology, 2006,212(3):238⁃249. doi: 10.1159/000091251. |
[223] | Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study[J]. Arthritis Rheum, 1999,42(11):2325⁃2329. doi: 10.1002/1529⁃0131(199 911)42:113.0.CO;2⁃C. |
[224] | Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate⁃naive patients: the RESPOND study[J]. Ann Rheum Dis, 2012,71(4):541⁃548. doi: 10.1136/ard.2011.152223. |
[225] | Kavanaugh A, Menter A, Mendelsohn A, et al. Effect of ustekinumab on physical function and health⁃related quality of life in patients with psoriatic arthritis: a randomized, placebo⁃controlled, phase II trial[J]. Curr Med Res Opin, 2010,26(10):2385⁃2392. doi: 10.1185/03007995.2010.515804. |
[226] | 谷雪虹, 苗钢, 龙振华. 雷公藤多甙片治疗银屑病关节炎疗效分析[J]. 中华皮肤科杂志, 2006,39(3):173. doi: 10.3760/j.issn:0412⁃4030.2006.03.023. |
[227] | Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives[J]. Psoriasis (Auckl), 2016,6:33⁃40. doi: 10.2147/PTT.S85330. |
[228] | Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails[J]. Dermatol Ther, 2018,31(3):e12589. doi: 10.1111/dth. 12589. |
[229] | Rogalski C. Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability[J]. Psoriasis (Auckl), 2015,5:97⁃107. doi: 10.2147/PTT.S63127. |
[230] | Torsekar R, Gautam MM. Topical therapies in psoriasis[J]. Indian Dermatol Online J, 2017,8(4):235⁃245. doi: 10.4103/2229⁃5178.209622. |
[231] | Samman PD, Fenton DA. The nails in disease[M]. 5th ed, London: Butterworth⁃Heinemann Ltd, 1994. |
[232] | Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy[J]. J Am Acad Dermatol, 2007,57(1):1⁃27. doi: 10.1016/j.jaad.2005.07.073. |
[233] | Armesto S, Esteve A, Coto⁃Segura P, et al. Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients[J]. Actas Dermosifiliogr, 2011,102(5):365⁃372. doi: 10.1016/j.ad. 2011.02.007. |
[234] | Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis⁃⁃clinically important, potentially treatable and often overlooked[J]. Rheumatology (Oxford), 2004,43(6):790⁃794. doi: 10.1093/rheumatology/keh 198. |
[235] | de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients[J]. Dermatology, 1996,193(4):300⁃303. doi: 10.1159/000246274. |
[236] | Pasch MC. Nail psoriasis: a review of treatment options[J]. Drugs, 2016,76(6):675⁃705. doi: 10.1007/s40265⁃016⁃0564⁃5. |
[237] | Fernández⁃Guarino M, Harto A, Sánchez⁃Ronco M, et al. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study[J]. J Eur Acad Dermatol Venereol, 2009,23(8):891⁃895. doi: 10.1111/j.1468⁃3083.2009.03196.x. |
[238] | Crowley JJ, Weinberg JM, Wu JJ, et al. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation[J]. JAMA Dermatol, 2015,151(1):87⁃94. doi: 10.1001/jamadermatol.2014.2983. |
[239] | Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey[J]. J Eur Acad Dermatol Venereol, 2005,19 Suppl 3:2⁃6. doi: 10.1111/j.1468⁃3083.2005.01329.x. |
[240] | Meeuwis KA, de Hullu JA, de Jager ME, et al. Genital psoriasis: a questionnaire⁃based survey on a concealed skin disease in the Netherlands[J]. J Eur Acad Dermatol Venereol, 2010,24(12):1425⁃1430. doi: 10.1111/j.1468⁃3083.2010.03663.x. |
[241] | Czuczwar P, Stępniak A, Goren A, et al. Genital psoriasis: a hidden multidisciplinary problem ⁃ a review of literature[J]. Ginekol Pol, 2016,87(10):717⁃721. doi: 10.5603/GP.2016.0074. |
[242] | Edwards SK, Bates CM, Lewis F, et al. 2014 UK national guideline on the management of vulval conditions[J]. Int J STD AIDS, 2015,26(9):611⁃624. doi: 10.1177/0956462414554271. |
[243] | Meeuwis KA, de Hullu JA, Massuger LF, et al. Genital psoriasis: a systematic literature review on this hidden skin disease[J]. Acta Derm Venereol, 2011,91(1):5⁃11. doi: 10. 2340/00015555⁃0988. |
[244] | American Academy of Dermatology Work Group, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case⁃based presentations and evidence⁃based conclusions[J]. J Am Acad Dermatol, 2011,65(1):137⁃174. doi: 10.1016/j.jaad.2010.11.055. |
[245] | Syed ZU, Khachemoune A. Inverse psoriasis: case presentation and review[J]. Am J Clin Dermatol, 2011,12(2):143⁃146. doi: 10.2165/11532060⁃000000000⁃00000. |
[246] | Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation[J]. J Am Acad Dermatol, 2009,60(1):120⁃124. doi: 10.1016/j.jaad.2008.06.041. |
[247] | Omland SH, Gniadecki R. Psoriasis inversa: a separate identity or a variant of psoriasis vulgaris? Clin Dermatol, 2015,33(4):456⁃461. doi: 10.1016/j.clindermatol.2015.04.007. |
[248] | Guglielmetti A, Conlledo R, Bedoya J, et al. Inverse psoriasis involving genital skin folds: successful therapy with dapsone[J]. Dermatol Ther (Heidelb), 2012,2(1):15. doi: 10.1007/s13555⁃012⁃0015⁃5. |
[249] | Beani JC, Jeanmougin M. Narrow⁃band UVB therapy in psoriasis vulgaris: good practice guideline and recommen⁃dations of the French Society of Photodermatology[J]. Ann Dermatol Venereol, 2010,137(1):21⁃31. doi: 10.1016/j.annder. 2009.12.004. |
[250] | Pavlovsky M, Baum S, Shpiro D, et al. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol, 2011,25(6):727⁃729. doi: 10. 1111/j.1468⁃3083.2010.03832.x. |
[251] | Pugashetti R, Koo J. Phototherapy in pediatric patients: choosing the appropriate treatment option[J]. Semin Cutan Med Surg, 2010,29(2):115⁃120. doi: 10.1016/j.sder.2010.03. 006. |
[252] | Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial. Lancet, 2017,390(10089):40⁃49. doi: 10.1016/S0140⁃6736(17)31189⁃3. |
[253] | Rose K, Happle R. The effect of regulation on pediatric psoriasis drug approvals: the challenge of the european union pediatric investigation plans[J]. Pediatr Dermatol, 2017,34(3):e154⁃e159. doi: 10.1111/pde.13097. |
[254] | Kurizky PS, Ferreira Cde C, Nogueira LS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding[J]. An Bras Dermatol, 2015,90(3):367⁃375. doi: 10.1590/abd1806⁃4841.20153113. |
[255] | Raychaudhuri SP, Navare T, Gross J, et al. Clinical course of psoriasis during pregnancy[J]. Int J Dermatol, 2003,42(7):518⁃520. doi: 10.1046/j.1365⁃4362.2003.01760.x. |
[256] | Pradat P, Robert⁃Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts[J]. Birth Defects Res A Clin Mol Teratol, 2003,67(12):968⁃970. doi: 10.1002/bdra.10134. |
[257] | Mygind H, Thulstrup AM, Pedersen L, et al. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy[J]. Acta Obstet Gynecol Scand, 2002,81(3):234⁃239. doi: 10.1034/ j.1600⁃0412.2002.810308.x. |
[258] | Mahé A, Perret JL, Ly F, et al. The cosmetic use of skin⁃lightening products during pregnancy in Dakar, Senegal: a common and potentially hazardous practice[J]. Trans R Soc Trop Med Hyg, 2007,101(2):183⁃187. doi: 10.1016/j.trstmh. 2006.06.007. |
[259] | Edwards MJ, Agho K, Attia J, et al. Case⁃control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy[J]. Am J Med Genet A, 2003,120A(4):459⁃463. doi: 10.1002/ajmg.a.20130. |
[260] | Chi CC, Mayon⁃White RT, Wojnarowska FT. Safety of topical corticosteroids in pregnancy: a population⁃based cohort study[J]. J Invest Dermatol, 2011,131(4):884⁃891. doi: 10.1038/jid.2010.392. |
[261] | Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts[J]. Am J Obstet Gynecol, 2007,197(6):585.e1⁃e7. doi: 10.1016/j.ajog.2007.05.046. |
[262] | Uchiyama H, Suzuki T, Koike Y, et al. Reproductive and developmental toxicity studies of calcipotriol (MC903): (3)⁃⁃a teratogenicity study in rabbits by subcutaneous administration[J]. J Toxicol Sci, 1996,21 Suppl 2:425⁃438. doi: 10.2131/jts.21.supplementii_425. |
[263] | El⁃Saie LT, Rabie AR, Kamel MI, et al. Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis[J]. Lasers Med Sci, 2011,26(4):481⁃485. doi: 10.1007/s10103⁃011⁃0895⁃0. |
[264] | Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients[J]. Joint Bone Spine, 2016,83(3):341⁃3. doi: 10.1016/j.jbspin.2015.07.004. |
[265] | Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future[J]. Expert Rev Clin Immunol, 2016,12(9):937⁃944. doi: 10.1080/1744666X.2016.1184973. |
[266] | Khan N, Asim H, Lichtenstein GR. Safety of anti⁃TNF therapy in inflammatory bowel disease during pregnancy[J]. Expert Opin Drug Saf, 2014,13(12):1699⁃1708. doi: 10.1517/147403 38.2014.973399. |
[267] | Clowse ME. The use of anti⁃TNFα medications for rheumatologic disease in pregnancy[J]. Int J Womens Health, 2010,2:199⁃209. |
[268] | Balato N, Patruno C, Napolitano M, et al. Managing moderate⁃to⁃severe psoriasis in the elderly[J]. Drugs Aging, 2014,31(4):233⁃238. doi: 10.1007/s40266⁃014⁃0156⁃6. |
[269] | Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris[J]. Eur J Dermatol, 2005,15(1):37⁃39. |
[270] | Bulur I, Erdogan HK, Aksu AE, et al. The efficacy and safety of phototherapy in geriatric patients: a retrospective study[J]. An Bras Dermatol, 2018,93(1):33⁃38. doi: 10.1590/abd1806⁃4841. 20185468. |
[271] | Garber C, Plotnikova N, Au SC, et al. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis[J]. J Drugs Dermatol, 2015,14(8):846⁃852. |
[272] | Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors[J]. Expert Opin Pharmacother, 2017,18(18):1965⁃1973. doi: 10. 1080/14656566.2017.1409205. |
[273] | 卢毅. “伏邪”理论在临床中的应用[J]. 中国中医急症, 2014,23(7):1295,1298. doi: 10.3969/j.issn.1004⁃745X.2014.07.034. |
[274] | 郭雯, 曹继伟, 郭建辉, 等. 从络病论治银屑病的理论探讨[J]. 中医临床研究, 2014,(4):74⁃75. doi: 10.3969/j.issn.1674⁃7860.2014.04.038. |
[275] | 中华中医药学会皮肤科分会. 皮肤科分会银屑病中医治疗专家共识(2017年版)[J]. 中国中西医结合皮肤性病学杂志, 2018,17(3):273⁃277. doi: 10.3969/j.issn.1672⁃0709.2018. 03.028. |
[276] | 赵炳南, 张志礼. 简明中医皮肤病学[M]. 北京: 中国中医药出版社, 2014:190⁃194. |
[277] | 瞿幸. 中医皮肤性病学[M]. 北京: 中国中医药出版社, 2009:168. |
[278] | 中华中医药学会皮肤科分会, 北京中医药学会皮肤病专业委员会, 北京中西医结合学会皮肤性病专业委员会. 寻常型银屑病(白疕)中医药循证临床实践指南(2013版)[J]. 中医杂志, 2014,55(1):76⁃82. doi: 10.13288/j.11⁃2166/r.2014.01. 021. |
[279] | 范瑞强, 邓丙戌, 杨志波. 中医皮肤性病学[M]. 北京: 科学技术文献出版社, 2010:470⁃486. |
[280] | 李冠汝, 郭昕炜, 孙丽蕴. 中医药治疗银屑病血燥证用药类别分析[J]. 中华中医药杂志, 2018,33(2):499⁃501. |
[281] | 范瑞强. 重症银屑病的中医治疗[J]. 江苏中医药, 2006,27(9):6. doi: 10.3969/j.issn.1672⁃397X.2006.09.003. |
[282] | Li N, Zhao W, Xing J, et al. Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood⁃heat syndrome: a multi⁃center, double⁃blind, randomized, placebo⁃controlled trial[J]. BMC Complement Altern Med, 2017,17(1):264. doi: 10.1186/s12906⁃017⁃1631⁃5. |
[283] | 杨素清, 李玲玉. 中药汤剂联合湿润烧伤膏治疗红皮病型银屑病的临床观察[J]. 中国烧伤创疡杂志, 2012,24(2):151⁃153. doi: 10.3969/j.issn.1001⁃0726.2012.02.015. |
[284] | 陈丽红, 赵文杰. 复方青黛膏治疗寻常型银屑病60例[J]. 光明中医, 2014,(7):1413⁃1414. doi: 10.3969/j.issn.1003⁃8914. 2014.07.028. |
[285] | 林胤谷, 吴宜鸿, 杨荣季, 等. 复方青黛油膏治疗银屑病的临床疗效评估[J]. 成都中医药大学学报, 2006,29(2):13⁃16. doi: 10.3969/j.issn.1004⁃0668.2006.02.005. |
[286] | Lin YK, Yen HR, Wong WR, et al. Successful treatment of pediatric psoriasis with Indigo naturalis composite ointment[J]. Pediatr Dermatol, 2006,23(5):507⁃510. doi: 10.1111/j. 1525⁃1470.2006.00295.x. |
[287] | Lin YK, See LC, Huang YH, et al. Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: a randomized, observer⁃blind, vehicle⁃controlled trial[J]. Phytomedicine, 2014,21(7):1015⁃1020. doi: 10.1016/j.phymed. 2014.02.013. |
[288] | 孙少馨, 瞿幸, 李玲玲, 等. 紫草油走罐治疗斑块型银屑病临床研究[J]. 现代中医临床, 2016,(1):29⁃32. doi: 10.3969/j.issn.2095⁃6606.2016.01.007. |
[289] | 中华人民共和国国家质量监督检验检疫总局, 中国国家标准化管理委员会. GB/T21709.6⁃2008 针灸技术操作规范第6部分: 穴位注射[S]. 北京: 2008. |
[290] | 张雷锋, 王飞宇. 中西医结合治疗银屑病150例疗效观察[J]. 长治医学院学报, 2008,22(3):229⁃230. doi: 10.3969/j.issn.1006⁃0588.2008.03.030. |
[291] | 陈云龙, 林研研, 陈珊珊, 等. 自血穴位注射治疗寻常型银屑病多中心疗效观察及对外周血IL⁃8、TNF⁃α的影向[J]. 甘肃中医学院学报, 2011,(3):48⁃50. doi: 10.3969/j.issn.1003⁃8450. 2011.03.023. |
[292] | 中国中西医结合学会皮肤性病学专业委员会特色疗法学组. 寻常型银屑病中医外治特色疗法专家共识(2017年)[J]. 中国中西医结合皮肤性病学杂志, 2017,16(6):547⁃550. doi: 10.3969/j.issn.1672⁃0709.2017.06.027. |
[293] | 广东省中医标准化技术委员会. DB44/T1423⁃2014寻常型银屑病中西医结合诊疗指南[S]. 广州: 广东省质量技术监督局, 2014. |
[294] | Lv M, Deng J, Tang N, et al. Efficacy and safety of Tripterygium Wilfordii Hook F on psoriasis vulgaris: a systematic review and meta⁃analysis of randomized controlled trials[J]. Evid Based Complement Alternat Med, 2018,2018:2623085. doi: 10.1155/2018/2623085. |
[295] | Yu JJ, Zhang CS, Coyle ME, et al. Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta⁃analysis of randomized controlled trials[J]. Curr Med Res Opin, 2017,33(2):279⁃287. doi: 10.1080/03007995.2016. 1254605. |
[296] | Brandrup F, Holm N, Grunnet N, et al. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution[J]. Acta Derm Venereol, 1982,62(3):229⁃236. |
[297] | Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs[J]. Arch Dermatol, 1974,109(2):207⁃211. |
[298] | Zhang X, Wang H, Te⁃Shao H, et al. The genetic epidemiology of psoriasis vulgaris in Chinese Han[J]. Int J Dermatol, 2002,41(10):663⁃669. doi: 10.1046/j.1365⁃4362.2002.01596.x. |
[1] | 孙小洁 刘毅. 抗雄激素药物治疗皮肤病研究进展[J]. 中华皮肤科杂志, 2023, 56(9): 882-885. |
[2] | 王钰倩 乔建军 方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2023, 56(9): 885-888. |
[3] | 刘元香 梁源 赵欣荣 孙玉娟 马琳 徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023, 56(9): 849-852. |
[4] | 刘小扬 赵琰 蔡林 张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848. |
[5] | 郭昊 刘辉 张丽 朱冠男 王平 姚志荣 高兴华 陈耀龙. 特应性皮炎诊疗指南(专科医生版本、全科医生版本和患者版本)计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814. |
[6] | 付丹丹 李佳林 付修宇 张芯育 胡华 宋向凤 田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844. |
[7] | 陈耀龙 刘辉 姚志荣 高兴华. 提升皮肤病领域指南和共识质量的策略与建议[J]. 中华皮肤科杂志, 2023, 56(9): 805-808. |
[8] | 袁心刚 倪思利 张建 罗晓燕 王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786. |
[9] | 钟洁敏 邵蕾 梁毅敏 黄琼霄 夏曼琪 刘玉梅. 射频火针与光动力疗法治疗面部中重度痤疮炎性皮损的疗效与安全性对比研究[J]. 中华皮肤科杂志, 2023, 56(8): 751-755. |
[10] | 宋志强 陈奇权 葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723. |
[11] | 王俊霞 郭伟楠 陈慧 郝军峰 李冰 卫静宜 赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765. |
[12] | 陈小敏 张景展 丁媛 康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802. |
[13] | 周彤 耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793. |
[14] | 李越 吴金燕 袁若月 杨屈杨 赵贤省 朱宁文. 细胞治疗遗传性大疱性表皮松解症研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 698-702. |
[15] | 蒋晓妍 高敏 张晓艳 刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692. |
|